Perennial Allergic Rhinitis - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Perennial Allergic Rhinitis - Pipeline Review, H2 2016’, provides an overview of the Perennial Allergic Rhinitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis

The report reviews pipeline therapeutics for Perennial Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Perennial Allergic Rhinitis therapeutics and enlists all their major and minor projects

The report assesses Perennial Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Perennial Allergic Rhinitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Faes Farma, S.A.

Glenmark Pharmaceuticals Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Merck & Co., Inc.

Pfizer Inc.

Shionogi & Co., Ltd.

VentiRx Pharmaceuticals, Inc.

Faes Farma, S.A.

Glenmark Pharmaceuticals Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Merck & Co., Inc.

Pfizer Inc.

Shionogi & Co., Ltd.

VentiRx Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Perennial Allergic ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Perennial Allergic Rhinitis Overview 6

Therapeutics Development 7

Pipeline Products for Perennial Allergic Rhinitis - Overview 7

Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis 8

Perennial Allergic Rhinitis - Therapeutics under Development by Companies 9

Perennial Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 10

Perennial Allergic Rhinitis - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Perennial Allergic Rhinitis - Products under Development by Companies 13

Perennial Allergic Rhinitis - Products under Investigation by Universities/Institutes 14

Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development 15

Faes Farma, S.A. 16

Glenmark Pharmaceuticals Ltd. 17

Hisamitsu Pharmaceutical Co., Inc. 18

Merck & Co., Inc. 19

Pfizer Inc. 20

Shionogi & Co., Ltd. 21

VentiRx Pharmaceuticals, Inc. 22

Perennial Allergic Rhinitis - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Combination Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

(levocabastine hydrochloride + mometasone furoate) - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

asapiprant - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

bilastine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

desloratadine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

emedastine difumarate - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

GSP-301 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

PF-06444752 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

PF-06444753 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

VTX-1463 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Perennial Allergic Rhinitis - Dormant Projects 47

Perennial Allergic Rhinitis - Discontinued Products 48

Perennial Allergic Rhinitis - Product Development Milestones 49

Featured News & Press Releases 49

Aug 13, 2015: PENDOPHARM announces Nasacort Allergy 24H Nasal Spray is now available without a prescription in Canadian Province 49

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

Contact Us 50

Disclaimer 51

List of Tables

List of Tables

Number of Products under Development for Perennial Allergic Rhinitis, H2 2016 7

Number of Products under Development for Perennial Allergic Rhinitis - Comparative ...

List of Tables

Number of Products under Development for Perennial Allergic Rhinitis, H2 2016 7

Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Perennial Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 15

Perennial Allergic Rhinitis - Pipeline by Faes Farma, S.A., H2 2016 16

Perennial Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 17

Perennial Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 18

Perennial Allergic Rhinitis - Pipeline by Merck & Co., Inc., H2 2016 19

Perennial Allergic Rhinitis - Pipeline by Pfizer Inc., H2 2016 20

Perennial Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2016 21

Perennial Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Assessment by Combination Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Perennial Allergic Rhinitis - Dormant Projects, H2 2016 47

Perennial Allergic Rhinitis - Discontinued Products, H2 2016 48

List of Figures

List of Figures

Number of Products under Development for Perennial Allergic Rhinitis, H2 2016 7

Number of Products under Development for Perennial Allergic Rhinitis - Comparative ...

List of Figures

Number of Products under Development for Perennial Allergic Rhinitis, H2 2016 7

Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports